Jeong Hee Cho-Vega, MD, PhD

 

To the Editor:

Paraneoplastic pemphigus (PNP), also known as paraneoplastic autoimmune multiorgan syndrome, is an autoimmune mucocutaneous blistering disease that typically occurs secondary to a lymphoproliferative disorder. Paraneoplastic pemphigus is characterized by severe erosive stomatitis, polymorphous skin lesions, and potential bronchiolitis obliterans that can mimic a wide array of conditions. The exact pathogenesis is unknown but is thought to be due to a combination of humoral and cell-mediated immunity. The condition usually confers a poor prognosis, with morbidity from 38% to upwards of 90%.¹

A 47-year-old man developed prominent pink to dusky, ill-defined, targetoid, coalescing papules over the back; violaceous macules over the palms and soles; and numerous crusted oral erosions while hospitalized for an infection. He had a history of stage IVB follicular lymphoma (double-hit type immunoglobulin heavy chain/BCL2 fusion and rearrangement of BCL6) complicated by extensive erosive skin lesions and multiple lines of infections. The clinical differential diagnosis included Stevens-Johnson syndrome vs erythema multiforme (EM) major secondary to administration of oxacillin vs PNP. Herpes simplex virus polymerase chain reaction and Mycoplasma titers were negative. Skin biopsies from the back and right abdomen revealed severe lichenoid interface dermatitis (IFD) with numerous dyskeratotic cells mimicking EM and eosinophils; however, direct immunofluorescence of the abdomen biopsy revealed an apparent suprabasal acantholysis with intercellular C3 in the lower half of the epidermis. Histologically, PNP was favored, but indirect immunofluorescence with monkey esophagus IgG was negative.

The skin lesions progressed, and an additional skin biopsy from the left arm performed 1 month later revealed similar histologic features with intercellular IgG and C3 in the lower half of the epidermis with weak basement membrane C3 (Figure 1). Serology also confirmed elevated serum antidesmoglein 1 and 3 antibodies. Thus, in the clinical setting of an erosive mucositis with EM-like and pemphigoidlike eruptions associated with B-cell lymphoma, the patient was diagnosed with PNP.

Despite multiple complications followed by intermittent treatments, the initial therapy with rituximab induction and subsequent cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) for the B-cell lymphoma was done during his hospital stay. Toward the end of his 8-week hospitalization, the patient was noted to have new lesions involving the hands, digits, and nails. The left hand showed anonychia of several fingers with prominent scarring (Figure 2A). There were large, verrucous, crusted plaques on the distal phalanges of several fingers on the right hand (Figure 2B). At that time, he was taking 20 mg daily of prednisone (for 10 months) and had completed his 6th cycle of R-CHOP, which resulted in improvement of the skin lesions. Oral steroids were tapered, and he was maintained on rituximab infusions every 8 weeks but has since been lost to follow-up.

Paraneoplastic lymphoma is a rare condition that affects 0.012% of non-Hodgkin lymphoma and chronic lymphocytic leukemia patients.² Reports of PNP involving the nails are even more rare, with 3 reports in the setting of underlying Castleman disease^3-5 and 2 reports in patients with underlying non-Hodgkin⁶ and follicular¹ lymphoma. These studies describe variable nail findings ranging from periungual erosions and edema, formation of dorsal pterygium, onycholysis with longitudinal furrowing, and destruction of the nail plate leading to onychomadesis and/or anonychia. These nail changes typically are seen in lichen planus or in bullous diseases affecting the basement membrane (eg, bullous pemphigoid, acquired epidermolysis bullosa) but not known in pemphigus, which is characterized by nonscarring nail changes.⁷

Although antidesmoglein 3 antibody was shown to be a pathologic driver in PNP, there is a weak correlation between antibody profiles and clinical presentation.⁸ In one case of PNP, antidesmoglein 3 antibody was negative, suggesting that lichenoid IFD may cause the phenotypic findings in PNP.⁹ Thus, the development of nail scarring in PNP may be explained by the presence of lichenoid IFD that is characteristic of PNP. However, the variation in antibody profile in PNP likely is a consequence of epitope spreading.

 

To the Editor:

Paraneoplastic pemphigus (PNP), also known as paraneoplastic autoimmune multiorgan syndrome, is an autoimmune mucocutaneous blistering disease that typically occurs secondary to a lymphoproliferative disorder. Paraneoplastic pemphigus is characterized by severe erosive stomatitis, polymorphous skin lesions, and potential bronchiolitis obliterans that can mimic a wide array of conditions. The exact pathogenesis is unknown but is thought to be due to a combination of humoral and cell-mediated immunity. The condition usually confers a poor prognosis, with morbidity from 38% to upwards of 90%.¹

A 47-year-old man developed prominent pink to dusky, ill-defined, targetoid, coalescing papules over the back; violaceous macules over the palms and soles; and numerous crusted oral erosions while hospitalized for an infection. He had a history of stage IVB follicular lymphoma (double-hit type immunoglobulin heavy chain/BCL2 fusion and rearrangement of BCL6) complicated by extensive erosive skin lesions and multiple lines of infections. The clinical differential diagnosis included Stevens-Johnson syndrome vs erythema multiforme (EM) major secondary to administration of oxacillin vs PNP. Herpes simplex virus polymerase chain reaction and Mycoplasma titers were negative. Skin biopsies from the back and right abdomen revealed severe lichenoid interface dermatitis (IFD) with numerous dyskeratotic cells mimicking EM and eosinophils; however, direct immunofluorescence of the abdomen biopsy revealed an apparent suprabasal acantholysis with intercellular C3 in the lower half of the epidermis. Histologically, PNP was favored, but indirect immunofluorescence with monkey esophagus IgG was negative.

The skin lesions progressed, and an additional skin biopsy from the left arm performed 1 month later revealed similar histologic features with intercellular IgG and C3 in the lower half of the epidermis with weak basement membrane C3 (Figure 1). Serology also confirmed elevated serum antidesmoglein 1 and 3 antibodies. Thus, in the clinical setting of an erosive mucositis with EM-like and pemphigoidlike eruptions associated with B-cell lymphoma, the patient was diagnosed with PNP.

Despite multiple complications followed by intermittent treatments, the initial therapy with rituximab induction and subsequent cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) for the B-cell lymphoma was done during his hospital stay. Toward the end of his 8-week hospitalization, the patient was noted to have new lesions involving the hands, digits, and nails. The left hand showed anonychia of several fingers with prominent scarring (Figure 2A). There were large, verrucous, crusted plaques on the distal phalanges of several fingers on the right hand (Figure 2B). At that time, he was taking 20 mg daily of prednisone (for 10 months) and had completed his 6th cycle of R-CHOP, which resulted in improvement of the skin lesions. Oral steroids were tapered, and he was maintained on rituximab infusions every 8 weeks but has since been lost to follow-up.

Paraneoplastic lymphoma is a rare condition that affects 0.012% of non-Hodgkin lymphoma and chronic lymphocytic leukemia patients.² Reports of PNP involving the nails are even more rare, with 3 reports in the setting of underlying Castleman disease^3-5 and 2 reports in patients with underlying non-Hodgkin⁶ and follicular¹ lymphoma. These studies describe variable nail findings ranging from periungual erosions and edema, formation of dorsal pterygium, onycholysis with longitudinal furrowing, and destruction of the nail plate leading to onychomadesis and/or anonychia. These nail changes typically are seen in lichen planus or in bullous diseases affecting the basement membrane (eg, bullous pemphigoid, acquired epidermolysis bullosa) but not known in pemphigus, which is characterized by nonscarring nail changes.⁷

Although antidesmoglein 3 antibody was shown to be a pathologic driver in PNP, there is a weak correlation between antibody profiles and clinical presentation.⁸ In one case of PNP, antidesmoglein 3 antibody was negative, suggesting that lichenoid IFD may cause the phenotypic findings in PNP.⁹ Thus, the development of nail scarring in PNP may be explained by the presence of lichenoid IFD that is characteristic of PNP. However, the variation in antibody profile in PNP likely is a consequence of epitope spreading.

 

To the Editor:

Paraneoplastic pemphigus (PNP), also known as paraneoplastic autoimmune multiorgan syndrome, is an autoimmune mucocutaneous blistering disease that typically occurs secondary to a lymphoproliferative disorder. Paraneoplastic pemphigus is characterized by severe erosive stomatitis, polymorphous skin lesions, and potential bronchiolitis obliterans that can mimic a wide array of conditions. The exact pathogenesis is unknown but is thought to be due to a combination of humoral and cell-mediated immunity. The condition usually confers a poor prognosis, with morbidity from 38% to upwards of 90%.¹

A 47-year-old man developed prominent pink to dusky, ill-defined, targetoid, coalescing papules over the back; violaceous macules over the palms and soles; and numerous crusted oral erosions while hospitalized for an infection. He had a history of stage IVB follicular lymphoma (double-hit type immunoglobulin heavy chain/BCL2 fusion and rearrangement of BCL6) complicated by extensive erosive skin lesions and multiple lines of infections. The clinical differential diagnosis included Stevens-Johnson syndrome vs erythema multiforme (EM) major secondary to administration of oxacillin vs PNP. Herpes simplex virus polymerase chain reaction and Mycoplasma titers were negative. Skin biopsies from the back and right abdomen revealed severe lichenoid interface dermatitis (IFD) with numerous dyskeratotic cells mimicking EM and eosinophils; however, direct immunofluorescence of the abdomen biopsy revealed an apparent suprabasal acantholysis with intercellular C3 in the lower half of the epidermis. Histologically, PNP was favored, but indirect immunofluorescence with monkey esophagus IgG was negative.

The skin lesions progressed, and an additional skin biopsy from the left arm performed 1 month later revealed similar histologic features with intercellular IgG and C3 in the lower half of the epidermis with weak basement membrane C3 (Figure 1). Serology also confirmed elevated serum antidesmoglein 1 and 3 antibodies. Thus, in the clinical setting of an erosive mucositis with EM-like and pemphigoidlike eruptions associated with B-cell lymphoma, the patient was diagnosed with PNP.

Despite multiple complications followed by intermittent treatments, the initial therapy with rituximab induction and subsequent cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) for the B-cell lymphoma was done during his hospital stay. Toward the end of his 8-week hospitalization, the patient was noted to have new lesions involving the hands, digits, and nails. The left hand showed anonychia of several fingers with prominent scarring (Figure 2A). There were large, verrucous, crusted plaques on the distal phalanges of several fingers on the right hand (Figure 2B). At that time, he was taking 20 mg daily of prednisone (for 10 months) and had completed his 6th cycle of R-CHOP, which resulted in improvement of the skin lesions. Oral steroids were tapered, and he was maintained on rituximab infusions every 8 weeks but has since been lost to follow-up.

Paraneoplastic lymphoma is a rare condition that affects 0.012% of non-Hodgkin lymphoma and chronic lymphocytic leukemia patients.² Reports of PNP involving the nails are even more rare, with 3 reports in the setting of underlying Castleman disease^3-5 and 2 reports in patients with underlying non-Hodgkin⁶ and follicular¹ lymphoma. These studies describe variable nail findings ranging from periungual erosions and edema, formation of dorsal pterygium, onycholysis with longitudinal furrowing, and destruction of the nail plate leading to onychomadesis and/or anonychia. These nail changes typically are seen in lichen planus or in bullous diseases affecting the basement membrane (eg, bullous pemphigoid, acquired epidermolysis bullosa) but not known in pemphigus, which is characterized by nonscarring nail changes.⁷

Although antidesmoglein 3 antibody was shown to be a pathologic driver in PNP, there is a weak correlation between antibody profiles and clinical presentation.⁸ In one case of PNP, antidesmoglein 3 antibody was negative, suggesting that lichenoid IFD may cause the phenotypic findings in PNP.⁹ Thus, the development of nail scarring in PNP may be explained by the presence of lichenoid IFD that is characteristic of PNP. However, the variation in antibody profile in PNP likely is a consequence of epitope spreading.